Eli Lilly and Company News Releases https://investor.lilly.com/ Eli Lilly and Company News Releases en Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-long-term-phase-3 NEW YORK & INDIANAPOLIS--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab Thu, 18 Apr 2019 17:30:00 -0400 Eli Lilly and Company News Releases 41161 Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement https://investor.lilly.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-first-quarter-2019 INDIANAPOLIS , April 10, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's Wed, 10 Apr 2019 16:30:00 -0400 Eli Lilly and Company News Releases 41121 Lilly and ImmuNext Announce Licensing and Research Collaboration https://investor.lilly.com/news-releases/news-release-details/lilly-and-immunext-announce-licensing-and-research-collaboration INDIANAPOLIS and LEBANON, N.H. , March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for autoimmune diseases by Tue, 26 Mar 2019 16:30:00 -0400 Eli Lilly and Company News Releases 41071 Survey Reveals Genital Psoriasis May Reduce Patients’ Self-Confidence and Hinder Them from Having Close Relationships https://investor.lilly.com/news-releases/news-release-details/survey-reveals-genital-psoriasis-may-reduce-patients-self INDIANAPOLIS, March 21, 2019 – Eli Lilly and Company (NYSE:LLY) announced today findings from a quantitative opinion survey, which found that people with genital psoriasis can experience reduced self-confidence and struggle to have close relationships. Thu, 21 Mar 2019 21:00:00 -0400 Eli Lilly and Company News Releases 41041 NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology https://investor.lilly.com/news-releases/news-release-details/nccn-announces-six-quality-improvement-projects-gastric-cancer PLYMOUTH MEETING, Pa. and INDIANAPOLIS , March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ® ) Oncology Research Program ( ORP ) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the delivery of gastric and gastroesophageal Wed, 20 Mar 2019 08:45:00 -0400 Eli Lilly and Company News Releases 41011 Lilly Announces Final Results of Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-final-results-elanco-exchange-offer INDIANAPOLIS , March 13, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) previously owned by Lilly, which expired at Wed, 13 Mar 2019 08:48:00 -0400 Eli Lilly and Company News Releases 40986 Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-phase-3-relay-trial-met-primary Global, randomized, placebo-controlled study confirms CYRAMZA, in combination with erlotinib, significantly delayed disease progression in previously untreated patients with metastatic non-small cell lung cancer whose tumors have activating EGFR mutations Global regulatory submissions to be Tue, 12 Mar 2019 06:45:00 -0400 Eli Lilly and Company News Releases 40981 Lilly Announces Preliminary Results of Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-preliminary-results-elanco-exchange-offer INDIANAPOLIS , March 11, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Mon, 11 Mar 2019 06:45:00 -0400 Eli Lilly and Company News Releases 40956 Lilly to Participate in Barclays Global Healthcare Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-barclays-global-healthcare-conference-2 INDIANAPOLIS , March 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Daniel Skovronsky , M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories , will Fri, 08 Mar 2019 07:30:00 -0500 Eli Lilly and Company News Releases 40946 Lilly to Participate in Cowen Health Care Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-cowen-health-care-conference-0 INDIANAPOLIS , March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cowen and Company 39 th Annual Health Care Conference on Monday, March 11, 2019 . Joshua Smiley , senior vice president and Lilly's chief financial officer, will participate in a fireside chat at Thu, 07 Mar 2019 17:15:00 -0500 Eli Lilly and Company News Releases 40936 Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer https://investor.lilly.com/news-releases/news-release-details/lilly-announces-final-exchange-ratio-45121-elanco-exchange-offer INDIANAPOLIS , March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly. Thu, 07 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40916 Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults https://investor.lilly.com/news-releases/news-release-details/lilly-receives-fda-priority-review-designation-emgalityr INDIANAPOLIS , March 5, 2019 /PRNewswire/ --   Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration ( FDA ) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality ® (galcanezumab-gnlm) injection for the preventive Tue, 05 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40896 Lilly to Introduce Lower-Priced Insulin https://investor.lilly.com/news-releases/news-release-details/lilly-introduce-lower-priced-insulin Authorized generic version of Humalog will be available in U.S. pharmacies at 50 percent lower list price INDIANAPOLIS , March 4, 2019 /PRNewswire/ -- Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will Mon, 04 Mar 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40881 Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting https://investor.lilly.com/news-releases/news-release-details/lilly-present-data-demonstrating-continued-scientific - Over 25 abstracts for medicines in Lilly's dermatology portfolio, including Taltz® (ixekizumab), highlight new findings for the treatment of patients with moderate-to-severe plaque psoriasis, including genital psoriasis and active psoriatic arthritis - INDIANAPOLIS , March 1, 2019 /PRNewswire/ Fri, 01 Mar 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40866 Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-phase-3-study NEW YORK and INDIANAPOLIS , Feb. 19, 2019 /PRNewswire/ --  Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). Tue, 19 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40686 Lilly Completes Acquisition of Loxo Oncology https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-loxo-oncology INDIANAPOLIS , Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology , Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a Fri, 15 Feb 2019 09:23:00 -0500 Eli Lilly and Company News Releases 40671 Lilly To Participate in Leerink Partners Global Healthcare Conference https://investor.lilly.com/news-releases/news-release-details/lilly-participate-leerink-partners-global-healthcare-conference INDIANAPOLIS , Feb. 14, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 . Christi Shaw , president of Lilly Bio-Medicines, will participate in a fireside chat at 1:00 p.m., Eastern Time. Thu, 14 Feb 2019 16:30:00 -0500 Eli Lilly and Company News Releases 40661 Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://investor.lilly.com/news-releases/news-release-details/boehringer-ingelheim-and-lilly-announce-carolinar-cardiovascular - Tradjenta (linagliptin) demonstrated no increased cardiovascular risk compared with glimepiride in adults with type 2 diabetes and cardiovascular risk - With a median follow-up of more than 6 years, CAROLINA adds evidence to the long-term safety profile of Tradjenta RIDGEFIELD, Conn. Thu, 14 Feb 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40641 Lilly to Participate in Guggenheim Healthcare Talks Idea Forum https://investor.lilly.com/news-releases/news-release-details/lilly-participate-guggenheim-healthcare-talks-idea-forum INDIANAPOLIS , Feb. 8, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019 . Anne White , president of Lilly Oncology, and Levi Garraway , M.D., Ph.D., senior vice president, oncology research and Fri, 08 Feb 2019 13:00:00 -0500 Eli Lilly and Company News Releases 40536 Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health https://investor.lilly.com/news-releases/news-release-details/lilly-will-initiate-divestiture-its-remaining-interest-elanco Provides Lilly shareholders opportunity for tax-free exchange INDIANAPOLIS , Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN). Fri, 08 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40516 Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology https://investor.lilly.com/news-releases/news-release-details/lilly-reports-strong-fourth-quarter-and-full-year-2018-financial - Fourth-quarter 2018 revenue increased 5 percent, driven by increased demand for newer medicines, while operating expenses increased 1 percent. Full-year 2018 revenue increased 7 percent to $24.556 billion. - Fourth-quarter 2018 earnings per share (EPS) grew to $1.10 on a reported basis, or $1.33 Wed, 06 Feb 2019 06:25:00 -0500 Eli Lilly and Company News Releases 40401 Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis https://investor.lilly.com/news-releases/news-release-details/lilly-announces-top-line-phase-3-results-baricitinib-patients INDIANAPOLIS , Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the Mon, 04 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40321 Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction https://investor.lilly.com/news-releases/news-release-details/lilly-and-loxo-oncology-announce-expiration-hsr-act-waiting INDIANAPOLIS and STAMFORD, Conn. , Feb. 1, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) (" Loxo Oncology ") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended Fri, 01 Feb 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40271 FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer https://investor.lilly.com/news-releases/news-release-details/fda-expands-lillys-alimtar-pemetrexed-label-combination New approval based on Phase 3 KEYNOTE-189 results INDIANAPOLIS , Jan. 31, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration ( FDA ) has granted approval for a new indication for ALIMTA ® (pemetrexed for injection) in combination with Thu, 31 Jan 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40266 Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement https://investor.lilly.com/news-releases/news-release-details/lilly-revises-date-fourth-quarter-2018-financial-results INDIANAPOLIS , Jan. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now announce results on Wednesday, February 6, 2019 , one week earlier than previously scheduled. Wed, 30 Jan 2019 15:15:00 -0500 Eli Lilly and Company News Releases 40261 Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain https://investor.lilly.com/news-releases/news-release-details/pfizer-and-lilly-announce-top-line-results-second-phase-3-study NEW YORK & INDIANAPOLIS --(BUSINESS WIRE)--Jan. 29, 2019-- Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. Tue, 29 Jan 2019 06:30:00 -0500 Eli Lilly and Company News Releases 40256 Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin https://investor.lilly.com/news-releases/news-release-details/government-employees-affected-federal-shutdown-encouraged Helpline available Monday through Friday at (833) 808-1234 INDIANAPOLIS , Jan. 23, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution Center and check whether they are receiving Wed, 23 Jan 2019 08:00:00 -0500 Eli Lilly and Company News Releases 40226 Lilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement https://investor.lilly.com/news-releases/news-release-details/lilly-confirms-date-and-conference-call-fourth-quarter-2018 INDIANAPOLIS , Jan. 21, 2019 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the Mon, 21 Jan 2019 16:15:00 -0500 Eli Lilly and Company News Releases 40221 Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients https://investor.lilly.com/news-releases/news-release-details/lilly-phase-3-reach-2-trial-data-published-lancet-oncology-shows REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials showed an improvement of 3.1 months in median overall survival INDIANAPOLIS , Jan. Fri, 18 Jan 2019 19:02:00 -0500 Eli Lilly and Company News Releases 40216 Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO® https://investor.lilly.com/news-releases/news-release-details/lilly-reports-results-phase-3-soft-tissue-sarcoma-study - Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population. - There were no new safety signals identified and the safety profile was Fri, 18 Jan 2019 06:45:00 -0500 Eli Lilly and Company News Releases 40206